Albumedix Ltd., a leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, is expanding its existing collaboration with Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.    This announcement comes on the back of the recent approval of Valneva´s inactivated COVID-19 vaccine (VLA2001) by MHRA, for which Valneva signed an agreement in November 2021 with the Europe...